Anika Therapeutics, a global orthopedic medicines company, had its first patient enroll in its HYALOFAST FastTRACK Phase III clinical study.
Researchers will analyze nearly 200 patients at 30 sites throughout the United States.
Here are five takeaways:
1. The study is a prospective, randomized, active treatment-controlled evaluator-binded multicenter study.
2. The study aims to establish that hyaluronan-based scaffold with autologous bone marrow aspirate concentrate is the best treatment for articular knee cartilage defect lesions.
3. Anika Therapeutics' HYALOFAST is a biodegradable scaffold that facilitates cartilage regeneration in patients with cartilage defects.
4. In Europe, patients treated with HYALOFAST successfully regenerated hyaline-like cartilage.
5. Anika Therapeutics specializes in therapeutics based on its proprietary hyaluronic acid technology.
More articles on orthopedics:
Orthopedic surgeon to know: Dr. Matthew Beal of Northwestern Medicine
Orthofix shares witness high volume increase: 5 facts
Distracted walking causes more injuries and hospital visits — 5 takeaways